Mixed results for TopiVert's dry eye drug candidate

7 August 2019

UK clinical-stage biotech TopiVert Pharma today announced mixed top-line results from THEIA-1 Phase IIb/III clinical study evaluating TOP1630, a novel anti-inflammatory kinase inhibitor, as an ophthalmic solution for the treatment of dry eye disease.

THEIA-1, a multicenter, randomized, double-masked, placebo-controlled Phase IIb/III study, investigated the efficacy and safety of TOP1630 0.1% Ophthalmic Solution compared to vehicle control (placebo) over a four-week period in 202 adult patients with moderate to severe dry eye disease.

The primary endpoints of the study, the efficacy of TOP1630 0.1% Ophthalmic Solution compared to placebo at day 29 on ocular grittiness and total ocular surface staining, were not met. However, TOP1630 showed statistically- and clinically-relevant improvements on multiple pre-specified endpoints compared to placebo including ocular discomfort, eye dryness and the Ocular Surface Disease Index (OSDI; Allergan, Irvine, CA).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK